Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Univec (UNVC) -- Ignore unavailable to you. Want to Upgrade?

To: Courtney Willfore who wrote (81)	11/7/1997 11:03:00 PM
From: r. peter Dale	Read Replies (1) \| Respond to of 181

<<way t'go>> I've known souls tied down and forced to listen to The Squirrel Nut Zippers for lesser double entendres than that. Shame. BTW, in your research for macrophage effectors, there are two interesting papers in the 11/97 edition of The Journal of Neurochemistry. They report on the interaction between superoxide dismutase (SOD) and nitric oxide (NO) (A mutation in an isoform of SOD is associated with ALS). In short, a mutated SOD is shown to significantly elevate nitrotyrosine - i.e. a dysfunctional SOD leads to higher NO related toxicity. Check it out. If a Pharma could block some of these macrophage pathways there would be some happy shareholders. Peter